Fluticasone propionate nasal spray was more effective than oral montelukast in controlling nasal symptoms in patients with asthma and allergic rhinitis who were also receiving inhaled salmeterol/fluticasone propionate, according to results from a study presented at the 60th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) [San Francisco, US; March 2004]. Both fluticasone propionate and montelukast provided significant improvements from baseline in nasal symptoms in this 4-week study; however, this effect was more marked with the fluticasone propionate nasal spray. Neither agent produced further improvements in morning peak expiratory flow (PEF), the primary efficacy endpoint for asthma control, compared with twice-daily doses of inhaled salmeterol/fluticasone propionate. Importantly, patients receiving intranasal fluticasone propionate reported higher levels of satisfaction with their study medication than those treated with montelukast.